Gilead, PAHO Partner for HIV Prevention Drug Access in Latin America
Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to improve access to HIV prevention drugs in Latin America and the Caribbean.
Source: GNews India BiotechGilead Sciences, a biopharmaceutical company, and the Pan American Health Organization (PAHO) have announced a new agreement. This partnership aims to expand access to Gilead's HIV prevention medicines, specifically pre-exposure prophylaxis (PrEP), across 35 countries and territories in Latin America and the Caribbean. The agreement will make these crucial drugs more affordable and available to people at high risk of HIV infection in the region. PAHO will work with its member states to facilitate the procurement and distribution of these medicines. This initiative is a significant step towards achieving the global goal of ending the HIV epidemic by increasing the reach of effective prevention strategies. Gilead's commitment through this agreement supports public health efforts to reduce new HIV infections.
This agreement is important for competitive exams as it highlights international cooperation in public health, a key topic for UPSC GS Paper II (Health, International Relations) and SSC General Awareness. It demonstrates how pharmaceutical companies and global health organizations collaborate to address major diseases like HIV. Aspirants should note the roles of PAHO and Gilead, and the concept of PrEP in disease prevention, which can appear in Science & Technology sections.
- Gilead Sciences and PAHO signed an agreement for HIV prevention drug access.
- The agreement covers 35 countries and territories in Latin America and the Caribbean.
- The primary drug involved is pre-exposure prophylaxis (PrEP) for HIV prevention.
- PAHO will help member states procure and distribute these medicines.
- The initiative aims to make HIV prevention drugs more affordable and accessible.
- This partnership supports the global goal of ending the HIV epidemic.
Gilead Sciences is an American biopharmaceutical company that researches, develops, and commercializes antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, and influenza. Founded in 1987, it is headquartered in Foster City, California. Gilead is known for its innovative medicines that have significantly impacted global health.
The Pan American Health Organization (PAHO) is an international public health agency working to improve health and living standards of the people of the Americas. It serves as the regional office for the Americas of the World Health Organization (WHO) and is the specialized health agency of the inter-American system. PAHO was founded in 1902 and is headquartered in Washington, D.C.
Pre-exposure prophylaxis (PrEP) is a method where people at high risk of HIV take antiretroviral medicines to prevent HIV infection. When taken consistently, PrEP has been shown to reduce the risk of HIV infection by over 90%. It is a key tool in HIV prevention strategies globally.
Exams often test knowledge of international health organizations like PAHO/WHO and major diseases like HIV. Be prepared for questions on their functions, headquarters, and key initiatives. Also, understand basic concepts of disease prevention and treatment.
Remember 'Gilead PAHO PrEP' as 'Good People Prevent Epidemics' to link the key entities and the purpose of the agreement.
Frequently Asked Questions
What is the purpose of the agreement between Gilead and PAHO for HIV prevention?
The agreement between Gilead and PAHO aims to increase access to affordable HIV prevention drugs, specifically PrEP, in 35 countries and territories across Latin America and the Caribbean. This initiative seeks to reduce new HIV infections and support public health efforts in the region.
Which specific region will benefit from the Gilead-PAHO HIV prevention drug access agreement?
The agreement will benefit countries and territories in the Latin America and Caribbean region. This includes 35 specific nations and territories that are member states of PAHO, ensuring a broad reach for the HIV prevention drugs.
What is PrEP and how does it help in HIV prevention?
PrEP, or pre-exposure prophylaxis, is a medication taken by HIV-negative individuals at high risk of exposure to prevent HIV infection. It involves taking antiretroviral drugs consistently, which can reduce the risk of contracting HIV by over 90% when used correctly, acting as a protective barrier against the virus.